BAY D 2472Alternative Names: BAYD 2472; BAYD 4160
Latest Information Update: 23 Sep 2010
At a glance
- Originator Bayer
- Mechanism of Action Phospholipase A2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 11 Jan 1999 New profile
- 11 Jan 1999 Preclinical development for Myocardial infarction in Germany (Unknown route)